scholarly journals Editorial on Special Issue “Tuberculosis Drug Discovery and Development 2019”

2020 ◽  
Vol 10 (17) ◽  
pp. 6069
Author(s):  
Claudia Sala ◽  
Laurent Roberto Chiarelli ◽  
Giovanna Riccardi

Mycobacterium tuberculosis, the etiological agent of human tuberculosis (TB), represents a global challenge to human health since it is the main cause of death by an infectious disease worldwide [...]

ADMET & DMPK ◽  
2021 ◽  
Vol 9 (4) ◽  
pp. 227-230
Author(s):  
Manfred Kansy ◽  
Giulia Caron

New Therapeutic Modalities in Drug Discovery and Development: Insights & Opportunities (Editorial for the special issue of ADMET and DMPK)


2021 ◽  
Author(s):  
Xuanxiu Ren ◽  
Wenqi Dong ◽  
Jiajia Feng ◽  
Pei Li ◽  
Yucheng Zheng ◽  
...  

Mycobacterium tuberculosis is a chronic infectious disease pathogen. To date, tuberculosis is a major infectious disease that endangers human health. To better prevent and treat tuberculosis, it is important to study the pathogenesis of M. tb . Based on early-stage laboratory research results, in this study, we verified the upregulation of sod2 in Bacillus Calmette–Guérin ( BCG ) and H37Rv infection. By detecting BCG / H37Rv intracellular survival in sod2 -silenced and sod2 - overexpressing macrophages, sod2 was found to promote the intracellular survival of BCG / H37Rv. Then, miR-495 was determined to be downregulated by BCG / H37Rv . BCG / H37Rv can upregulate sod2 expression by miR-495 to promote the intracellular survival of BCG / H37Rv through a decline in ROS levels. This study provides a theoretical basis for developing new drug targets and treating tuberculosis.


Author(s):  
Daniele Zampieri ◽  
Maria G. Mamolo

: Tuberculosis is one of the top 10 causes of death worldwide and the leading cause of death from a single infectious agent mainly due to Mycobacterium tuberculosis (MTB). Recently, clinical prognoses have worsened due to the emergence of multi-drug resistant (MDR) and extensive-drug resistant (XDR) tuberculosis which lead to the need of new, efficient and safely drugs. Among the several strategies, polypharmacology could be considered one of the best solutions, in particular the multi-target directed ligands strategy (MTDLs), based on the synthesis of hybrid ligands acting against two targets of the pathogen. The framework strategy comprises linking, fusing and merging approaches to develop new chemical entities. With these premises, this review aims to provide an overview of recent hybridization approach, in medicinal chemistry, of the most recent and promising multitargeting antimycobacterial candidates.


Micromachines ◽  
2021 ◽  
Vol 12 (8) ◽  
pp. 875
Author(s):  
Tuhin Subhra Santra ◽  
Fan-Gang Tseng

The functional, genetic, or compositional heterogeneity of healthy and diseased tissues promotes significant challenges to drug discovery and development [...]


Marine Drugs ◽  
2018 ◽  
Vol 16 (10) ◽  
pp. 376 ◽  
Author(s):  
Danielle Demers ◽  
Matthew Knestrick ◽  
Renee Fleeman ◽  
Rahmy Tawfik ◽  
Ala Azhari ◽  
...  

There is an acute need for new and effective agents to treat infectious diseases. We conducted a screening program to assess the potential of mangrove-derived endophytic fungi as a source of new antibiotics. Fungi cultured in the presence and absence of small molecule epigenetic modulators were screened against Mycobacterium tuberculosis and the ESKAPE panel of bacterial pathogens, as well as two eukaryotic infective agents, Leishmania donovani and Naegleria fowleri. By comparison of bioactivity data among treatments and targets, trends became evident, such as the result that more than 60% of active extracts were revealed to be selective to a single target. Validating the technique of using small molecules to dysregulate secondary metabolite production pathways, nearly half (44%) of those fungi producing active extracts only did so following histone deacetylase inhibitory (HDACi) or DNA methyltransferase inhibitory (DNMTi) treatment.


2020 ◽  
Vol 2 (2) ◽  
pp. 1-5
Author(s):  
Aarajana Shrestha ◽  
Tara Man Kadayat

COVID-19 Special Issue: Coronavirus Disease 2019 (COVID-19) has emerged as a global threat. Scientists and clinicians are endeavoring to find effective drugs and vaccines for this disease. This special issue of the Europasian Journal of Medical Sciences (EJMS) aims to cover the problems, solutions, and challenges of COVID-19 around the world. In this Editorial, EJMS Editors Aarajana Shrestha and Tara Man Kadayat highlight the processes of drug discovery and development and a brief overview of the current drug development strategies against COVID-19.


Sign in / Sign up

Export Citation Format

Share Document